Ursula Winter1,2, Daiana Ganiewich1,3, Daniela Ottaviani4, Santiago Zugbi1,2, Rosario Aschero2,5, Juan Martin Sendoya3, Eduardo G Cafferata2,3, Marcela Mena1, Mariana Sgroi6, Claudia Sampor7, Fabiana Lubieniecki5, Adriana Fandiño6, Martin C Abba2,8, François Doz9, Osvaldo Podhjacer2,3, Angel Montero Carcaboso10, Eric Letouzé11,12, François Radvanyi4, Guillermo L Chantada1,2, Andrea S Llera2,3, Paula Schaiquevich1,2. 1. Precision Medicine, Hospital de Pediatría J.P. Garrahan, Buenos Aires, Argentina. 2. National Scientific and Technical Research Council, CONICET, Buenos Aires, Argentina. 3. Laboratory of Molecular and Cellular Therapy, Instituto Leloir, Buenos Aires, Argentina. 4. Centre National de la Recherche Scientifique, Unité Mixte de Recherche 144, Institut Curie, Paris, France. 5. Pathology Service, Hospital de Pediatría J.P. Garrahan, Buenos Aires, Argentina. 6. Ophthalmology Service, Hospital de Pediatría J.P. Garrahan, Buenos Aires, Argentina. 7. Oncology Service, Hospital de Pediatría J.P. Garrahan, Buenos Aires, Argentina. 8. Centro de Investigaciones Inmunológicas Básicas y Aplicadas, School of Medical Sciences, Universidad de La Plata, La Plata, Argentina. 9. Soins, Innovation, Recherche, en Oncologie de l'Enfant, de l'Adolescent et de l'Adulte Jeune (SIREDO) Oncology Center, Institut Curie, Paris, France. 10. Preclinical Therapeutics and Drug Delivery Research Program and Department of Pediatric Hematology and Oncology, Hospital Sant Joan de Deu, Barcelona, Spain. 11. Centre de Recherche des Cordeliers, Sorbonne Universités, Institut National de la Santé et de la Recherche Médicale, Paris, France. 12. Functional Genomics of Solid Tumor, Labex Immuno-Oncology, Équipe Labellisée Ligue Contre le Cancer, Université de Paris, Université Paris 13, Paris, France.
Abstract
Importance: Comprehensive understanding of the genomic and gene-expression differences between retinoblastoma tumors from patients with bilateral disease may help to characterize risk and optimize treatment according to individual tumor characteristics. Objective: To compare the genomic features between each eye and a specimen from an orbital relapse in patients with bilateral retinoblastoma. Design, Setting, and Participants: In this case, 2 patients with retinoblastoma underwent upfront bilateral enucleation. Tumor samples were subjected to genomic and gene-expression analysis. Primary cell cultures were established from both of the tumors of 1 patient and were used for gene-expression studies. Main Outcomes and Measures: Whole-exome sequencing was performed on an Illumina platform for fresh tumor samples and DNA arrays (CytoScan or OncoScan) were used for paraffin-embedded samples and cell lines. Gene-expression analysis was performed using Agilent microarrays. Germinal and somatic alterations, copy number alterations, and differential gene expression were assessed. Results: After initial bilateral enucleation, patient 1 showed massive choroidal and laminar optic nerve infiltration, while patient 2 showed choroidal and laminar optic nerve invasion. Patient 1 developed left-eye orbital recurrence and bone marrow metastasis less than 1 year after enucleation. Both ocular tumors showed gains on 1q and 6p but presented other distinct genomic alterations, including an additional gain in 2p harboring the N-myc proto-oncogene (MYCN) in the left tumor and orbital recurrence. Similar copy number alterations between the orbital recurrence and the left eye supported the origin of the relapse, with an additional 11q loss only detected in the orbital relapse. Specimens from patient 2 showed common copy number gains and losses, but further evolution rendered a 2p gain spanning MYCN in the left tumor. For this patient, microarray expression analysis showed differential expression of the MYCN and the forkhead box protein G1 (FOXG1) gene pathways between the left and right tumors. Conclusions and Relevance: Differential genomic and gene expression features were observed between tumors in 2 patients with bilateral disease, confirming intereye heterogeneity that might be considered if targeted therapies are used in such patients. Chromosomal alteration profile supported the origin of the orbital recurrence from the homolateral eye in 1 patient. Loss in chromosome 11q may have been associated with extraocular relapse in this patient.
Importance: Comprehensive understanding of the genomic and gene-expression differences between retinoblastoma tumors from patients with bilateral disease may help to characterize risk and optimize treatment according to individual tumor characteristics. Objective: To compare the genomic features between each eye and a specimen from an orbital relapse in patients with bilateral retinoblastoma. Design, Setting, and Participants: In this case, 2 patients with retinoblastoma underwent upfront bilateral enucleation. Tumor samples were subjected to genomic and gene-expression analysis. Primary cell cultures were established from both of the tumors of 1 patient and were used for gene-expression studies. Main Outcomes and Measures: Whole-exome sequencing was performed on an Illumina platform for fresh tumor samples and DNA arrays (CytoScan or OncoScan) were used for paraffin-embedded samples and cell lines. Gene-expression analysis was performed using Agilent microarrays. Germinal and somatic alterations, copy number alterations, and differential gene expression were assessed. Results: After initial bilateral enucleation, patient 1 showed massive choroidal and laminar optic nerve infiltration, while patient 2 showed choroidal and laminar optic nerve invasion. Patient 1 developed left-eye orbital recurrence and bone marrow metastasis less than 1 year after enucleation. Both ocular tumors showed gains on 1q and 6p but presented other distinct genomic alterations, including an additional gain in 2p harboring the N-myc proto-oncogene (MYCN) in the left tumor and orbital recurrence. Similar copy number alterations between the orbital recurrence and the left eye supported the origin of the relapse, with an additional 11q loss only detected in the orbital relapse. Specimens from patient 2 showed common copy number gains and losses, but further evolution rendered a 2p gain spanning MYCN in the left tumor. For this patient, microarray expression analysis showed differential expression of the MYCN and the forkhead box protein G1 (FOXG1) gene pathways between the left and right tumors. Conclusions and Relevance: Differential genomic and gene expression features were observed between tumors in 2 patients with bilateral disease, confirming intereye heterogeneity that might be considered if targeted therapies are used in such patients. Chromosomal alteration profile supported the origin of the orbital recurrence from the homolateral eye in 1 patient. Loss in chromosome 11q may have been associated with extraocular relapse in this patient.
Authors: Verónica Pérez; Claudia Sampor; Guadalupe Rey; Andreu Parareda-Salles; Katherine Kopp; Agustín P Dabezies; Gustavo Dufort; Marta Zelter; Juan P López; Marcelo Urbieta; Elisa Alcalde-Ruiz; Jaume Catala-Mora; Mariona Suñol; Diego Ossandon; Adriana C Fandiño; J Oscar Croxatto; María T G de Dávila; Gregory Reaman; Yaddanapudi Ravindranath; Guillermo L Chantada Journal: JAMA Ophthalmol Date: 2018-07-01 Impact factor: 7.389
Authors: MoonSun Jung; Amanda J Russell; Bing Liu; Joshy George; Pei Yan Liu; Tao Liu; Anna DeFazio; David D L Bowtell; André Oberthuer; Wendy B London; Jamie I Fletcher; Michelle Haber; Murray D Norris; Michelle J Henderson Journal: Cancer Res Date: 2016-12-06 Impact factor: 12.701
Authors: Diane E Rushlow; Berber M Mol; Jennifer Y Kennett; Stephanie Yee; Sanja Pajovic; Brigitte L Thériault; Nadia L Prigoda-Lee; Clarellen Spencer; Helen Dimaras; Timothy W Corson; Renée Pang; Christine Massey; Roseline Godbout; Zhe Jiang; Eldad Zacksenhaus; Katherine Paton; Annette C Moll; Claude Houdayer; Anthony Raizis; William Halliday; Wan L Lam; Paul C Boutros; Dietmar Lohmann; Josephine C Dorsman; Brenda L Gallie Journal: Lancet Oncol Date: 2013-03-13 Impact factor: 41.316
Authors: Branavan Manoranjan; Xin Wang; Robin M Hallett; Chitra Venugopal; Stephen C Mack; Nicole McFarlane; Sara M Nolte; Katrin Scheinemann; Thorsteinn Gunnarsson; John A Hassell; Michael D Taylor; Cathy Lee; Joanna Triscott; Colleen M Foster; Christopher Dunham; Cynthia Hawkins; Sandra E Dunn; Sheila K Singh Journal: Stem Cells Date: 2013-07 Impact factor: 6.277
Authors: Antonio Juan Ribelles; Sandra Barberá; Yania Yáñez; Pablo Gargallo; Vanessa Segura; Bárbara Juan; Rosa Noguera; Marta Piqueras; Victoria Fornés-Ferrer; Jaime Font de Mora; Adela Cañete; Victoria Castel Journal: Sci Rep Date: 2019-09-24 Impact factor: 4.379
Authors: Irsan E Kooi; Berber M Mol; Maarten P G Massink; Najim Ameziane; Hanne Meijers-Heijboer; Charlotte J Dommering; Saskia E van Mil; Yne de Vries; Annemarie H van der Hout; Gertjan J L Kaspers; Annette C Moll; Hein Te Riele; Jacqueline Cloos; Josephine C Dorsman Journal: Sci Rep Date: 2016-04-29 Impact factor: 4.379
Authors: Paula Schaiquevich; Jasmine H Francis; María Belén Cancela; Angel Montero Carcaboso; Guillermo L Chantada; David H Abramson Journal: Front Oncol Date: 2022-04-01 Impact factor: 5.738
Authors: María Belen Cancela; Santiago Zugbi; Ursula Winter; Ana Laura Martinez; Claudia Sampor; Mariana Sgroi; Jasmine H Francis; Ralph Garippa; David H Abramson; Guillermo Chantada; Paula Schaiquevich Journal: Invest New Drugs Date: 2020-11-16 Impact factor: 3.850
Authors: Elyssa Y Wong; Liya Xu; Lishuang Shen; Mary E Kim; Ashley Polski; Rishvanth K Prabakar; Rachana Shah; Rima Jubran; Jonathan W Kim; Jaclyn A Biegel; Xiaowu Gai; Peter Kuhn; James Hicks; Jesse L Berry Journal: NPJ Precis Oncol Date: 2021-07-27